Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

282
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
282
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

583
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
583
Self-Evaluation Maintenance Model01:29

Self-Evaluation Maintenance Model

339
The Self-Evaluation Maintenance (SEM) model offers a psychological framework to understand how individuals’ self-esteem is influenced by the achievements of others, particularly those with whom they share close personal bonds. The SEM model operates when personal rather than social identity guides individuals. Central to this model is the notion that individuals have an inherent desire to preserve a favorable self-image, which is continuously shaped by interpersonal comparisons and...
339
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

251
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
251
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

548
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
548

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and psychosocial factors predicting persistent smoking in hospitalized patients with atherosclerotic vascular disease: A prespecified analysis of two randomized controlled trials.

Tobacco prevention & cessation·2026
Same author

Reliable classification of polyps based on artificial intelligence: a development and validation study.

EClinicalMedicine·2026
Same author

Applicability of mitotic figure counting by deep learning: a development and pan-cancer validation study.

FEBS open bio·2026
Same author

Generalisation of automatic tumour segmentation in histopathological whole-slide images across multiple cancer types.

NPJ precision oncology·2026
Same author

Motivational smoking cessation counselling and community-based follow-up after hospitalisation for vascular disease: A randomised controlled trial.

Addiction (Abingdon, England)·2025
Same author

Gastrointestinal symptoms in adults with Fabry disease and their associations with physical and mental health.

BMC gastroenterology·2025
Same journal

Leveraging data-driven risk-adapted surveillance strategies after disease progression in locally advanced rectal cancer.

BMC cancer·2026
Same journal

Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade.

BMC cancer·2026
Same journal

Beyond side effects: treatment-related adverse events are associated with improved survival outcomes in HCC patients on atezolizumab-bevacizumab therapy.

BMC cancer·2026
Same journal

Clinical outcomes of percutaneous cryoablation for pulmonary metastases of soft tissue and bone sarcomas under local anesthesia: a single-institution retrospective cohort study.

BMC cancer·2026
Same journal

Catastrophic health expenditure and its determinant factors among patients with cancer attending Wolaita Sodo University Comprehensive Specialized Hospital, South Ethiopia.

BMC cancer·2026
Same journal

Single-session agreement of ChatGPT and Gemini treatment recommendations with multidisciplinary tumor board decisions in thoracic oncology.

BMC cancer·2026
See all related articles

Related Experiment Video

Updated: Feb 14, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.1K

Evaluating different breast tumor progression models using screening data.

Åsbjørn Schumacher Westvik1, Harald Weedon-Fekjær2, Jan Mæhlen1

  • 1Department of Pathology, Oslo University Hospital, Norway, P.O. Box 4956 Nydalen, 0424, Oslo, Norway.

BMC Cancer
|February 22, 2018
PubMed
Summary
This summary is machine-generated.

Mammography screening aims to detect breast cancer early. This study found that models assuming only progressive tumors cannot fully explain incidence trends after screening introduction, suggesting some tumors may regress or become less detectable.

Keywords:
Breast cancerHormone replacement therapyMammography screeningOver-diagnosisSimulation modelTumor regression

More Related Videos

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

24.0K
Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis
10:56

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis

Published on: August 1, 2019

8.8K

Related Experiment Videos

Last Updated: Feb 14, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.1K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

24.0K
Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis
10:56

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis

Published on: August 1, 2019

8.8K

Area of Science:

  • Oncology
  • Epidemiology
  • Biostatistics

Background:

  • Mammography screening detects breast cancer early, reducing mortality.
  • Traditionally, breast cancer has been viewed as solely progressive.
  • This study challenges the assumption of strictly progressive tumors in screening contexts.

Purpose of the Study:

  • To test if incidence levels after mammography screening introduction can be reproduced assuming only progressive tumors.
  • To evaluate the validity of the progressive tumor assumption in breast cancer screening.
  • To understand the dynamics of breast cancer incidence following screening implementation.

Main Methods:

  • Utilized breast cancer incidence data from Norwegian counties (1990-2009).
  • Simulated incidence levels using estimates of tumor growth and screening sensitivity (1990-1998) for the screening period (1999-2009).
  • Compared simulated incidence with observed levels, adjusting for factors like hormone replacement therapy.

Main Results:

  • Simulated incidence levels were significantly lower than observed levels during repeated screenings.
  • Results remained robust to model parameter changes.
  • Reproducing observed incidence required assuming some tumors undergo regression or become less detectable.

Conclusions:

  • Models with strictly progressive tumors partially explain incidence changes post-screening.
  • More complex tumor dynamics, including regression, are needed to explain observed incidence trends.
  • Findings question assumptions in over-diagnosis calculations and call for studies in diverse populations.